In this final part of the MHE 2021 Pharmacy Survey, participants share their thoughts on which federal policies they favor as a way to curb drug prices and which policy is more likely to occur this year. MHE's annual pharmacy survey had over 225 respondents.
In this part five series, participants give their opinions on which drugs newer to the market in the last 12 months hold the most promise to reducing morbidity and mortality. Participants also shared which drug in the pipeline holds the most promise. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next few days.
Predictions that the company would make a major move to dominate American healthcare have not come to pass. So far.
In this part four series, participants give their opinions on the biggest driver of specialty drug expenditures this year and what the most significant change in contracts between plan sponsors and PBMs could be in the near future. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next few days.
According to the CDC, use of any contraception has remained stable in the United States. From 2015 to 2017, approximately 2 out of 3 girls and women ages 15 to 49 used some form of contraception,and a similar proportion did so from 2017 to 2019.
The pandemic caused a temporary dip in 2020. But as public health spending has decreased, sexually transmitted disease trends have increased.
In this part three series, participants give their opinions on the most effective ways to reduce traditional and specialty pharmaceutical costs. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next several days.
In this part two series, participants give their opinions on the lasting effects of the pandemic. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next several days.
The latest technology is changing treatments for patients.
Respondents upbeat about COVID-19 vaccination. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next several days.
Research and investment are increasing into psilocybin and MDMA as treatments for several mental health disorders.
The jury is still out. Several companies have high hopes for candidates under development.
Harvard researchers say, well, maybe.
Ten years ago, specialty accounted for 15% to 20% of the money spent on drugs, according to Prem Shah, executive vice president of specialty pharmacy and product innovation at CVS Health.
